News & Insights
Exclusive: Brent Saunders’ latest dermatology bet gets $20M for skin longevity
In an Endpoints News exclusive, Brent shares the premise behind Rapalogix health and the company’s plans to change how we think about skin health.
AI could take ‘years’ off the drug development process, says Bausch + Lomb CEO Brent Saunders
Brent joined “Squawk on the Street” to discuss the impacts of artificial intelligence on health care, Bausch + Lomb’s latest earnings report, and more.
Bausch + Lomb CEO: Standing still is the new falling behind
In a piece for Fortune, Brent covers the AI upskilling imperative and why he we made AI training mandatory for 8,000+ employees at Bausch + Lomb.
Brent Saunders: Eyeing New Horizons
Pharmaceutical Executive highlights Bausch + Lomb’s transformation under Brent, with a focus on the company’s rebuilt pipeline.
Q&A: Brent Saunders on pushing Bausch out of neutral, scrutinizing new hires and why TrumpRx matters
Brent speaks with Senior Biopharma Correspondent Andrew Dunn for an Endpoints News feature.
Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical
Brent joins CNBC’s “Squawk Box” live in studio.
Exclusive: Brent Saunders’ latest dermatology bet gets $20M for skin longevity
In an Endpoints News exclusive, Brent shares the premise behind Rapalogix health and the company’s plans to change how we think about skin health.
AI could take ‘years’ off the drug development process, says Bausch + Lomb CEO Brent Saunders
Brent joined “Squawk on the Street” to discuss the impacts of artificial intelligence on health care, Bausch + Lomb’s latest earnings report, and more.
Bausch + Lomb CEO: Standing still is the new falling behind
In a piece for Fortune, Brent covers the AI upskilling imperative and why he we made AI training mandatory for 8,000+ employees at Bausch + Lomb.
Brent Saunders: Eyeing New Horizons
Pharmaceutical Executive highlights Bausch + Lomb’s transformation under Brent, with a focus on the company’s rebuilt pipeline.